← Back to Clinical Trials
Recruiting NCT06968611

NCT06968611 Improving Patient-centered Care for Diabetes in Bangladesh Through "Dynamic Integration" of Vision Care on the Demand Side

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06968611
Status Recruiting
Phase
Sponsor Orbis
Condition Diabetes Mellitus
Study Type INTERVENTIONAL
Enrollment 640 participants
Start Date 2025-08-25
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Education/information of riskFree eye glasses

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 640 participants in total. It began in 2025-08-25 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to determine whether there is an increase in participant uptake of diabetes mellitus (DM) and diabetic retinopathy (DR) services and improved quality of patient-centered diabetic care resulting from the use of automated voice message reminders to sensitize people with DM about the potential for sight loss alongside the provision of free reading glasses. The main questions it aims to answer are: 1. Will the proportion of patients completing their scheduled DR and DM appointments within 3 weeks of the scheduled date be significantly increased in the group receiving the automated voice messages containing both appointment reminders and messaging about the importance of visit and medication compliance in reducing the risk of vision loss, compared with participant messages which only remind them of their appointments? 2. What is the cost-effectiveness, measured as total intervention cost per additional patient complying with the suggested exam?

Eligibility Criteria

Inclusion Criteria: * Diagnosed with DM within the last 6 months * Over 30 years of age * Currently treated at the Dinajpur Diabetes Hospital * Possess a mobile phone to receive voice messages * Willingness to participate in the study, and ability to give informed consent Exclusion Criteria: * Other significant causes of vision loss * Medical conditions that could impair compliance with follow-up (such as stroke, dementia, etc.)

Contact & Investigator

Central Contact

Lutful Husain

✉ lutful.husain@orbis.org

📞 +88 01711626852

Principal Investigator

Munir Ahmed

PRINCIPAL INVESTIGATOR

Orbis Bangladesh

Frequently Asked Questions

Who can join the NCT06968611 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06968611 currently recruiting?

Yes, NCT06968611 is actively recruiting participants. Contact the research team at lutful.husain@orbis.org for enrollment information.

Where is the NCT06968611 trial being conducted?

This trial is being conducted at Dinajpur, Bangladesh, Dinajpur Sadar, Bangladesh.

Who is sponsoring the NCT06968611 clinical trial?

NCT06968611 is sponsored by Orbis. The principal investigator is Munir Ahmed at Orbis Bangladesh. The trial plans to enroll 640 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology